keyword
MENU ▼
Read by QxMD icon Read
search

"Health technology assessment"

keyword
https://www.readbyqxmd.com/read/28237205/value-assessment-frameworks-for-hta-agencies-the-organization-of-evidence-informed-deliberative-processes
#1
Rob Baltussen, Maarten Paul Maria Jansen, Leon Bijlmakers, Janneke Grutters, Anouck Kluytmans, Rob P Reuzel, Marcia Tummers, Gert Jan van der Wilt
Priority setting in health care has been long recognized as an intrinsically complex and value-laden process. Yet, health technology assessment agencies (HTAs) presently employ value assessment frameworks that are ill fitted to capture the range and diversity of stakeholder values and thereby risk compromising the legitimacy of their recommendations. We propose "evidence-informed deliberative processes" as an alternative framework with the aim to enhance this legitimacy. This framework integrates two increasingly popular and complementary frameworks for priority setting: multicriteria decision analysis and accountability for reasonableness...
February 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28237203/the-hta-core-model-%C3%A2-10-years-of-developing-an-international-framework-to-share-multidimensional-value-assessment
#2
Finn Børlum Kristensen, Kristian Lampe, Claudia Wild, Marina Cerbo, Wim Goettsch, Lidia Becla
BACKGROUND AND OBJECTIVES: The HTA Core Model(®) as a science-based framework for assessing dimensions of value was developed as a part of the European network for Health Technology Assessment project in the period 2006 to 2008 to facilitate production and sharing of health technology assessment (HTA) information, such as evidence on efficacy and effectiveness and patient aspects, to inform decisions. METHODS: It covers clinical value as well as organizational, economic, and patient aspects of technologies and has been field-tested in two consecutive joint actions in the period 2010 to 2016...
February 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28237197/toward-a-broader-concept-of-value-identifying-and-defining-elements-for-an-expanded-cost-effectiveness-analysis
#3
Louis P Garrison, Sachin Kamal-Bahl, Adrian Towse
This commentary identifies and defines potentially useful expansions to traditional cost-effectiveness analysis as often used in health technology assessment. Since the seminal 1977 article by Weinstein and Stason, the recommended approach has been the use of the incremental cost-effectiveness ratio based on the metric of the cost per quality-adjusted life-year gained, allowing comparisons across different technologies. An expanded framework, incorporating a wider range of the elements of value, is proposed...
February 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28237196/using-cost-effectiveness-analysis-to-address-health-equity-concerns
#4
Richard Cookson, Andrew J Mirelman, Susan Griffin, Miqdad Asaria, Bryony Dawkins, Ole Frithjof Norheim, Stéphane Verguet, Anthony J Culyer
This articles serves as a guide to using cost-effectiveness analysis (CEA) to address health equity concerns. We first introduce the "equity impact plane," a tool for considering trade-offs between improving total health-the objective underpinning conventional CEA-and equity objectives, such as reducing social inequality in health or prioritizing the severely ill. Improving total health may clash with reducing social inequality in health, for example, when effective delivery of services to disadvantaged communities requires additional costs...
February 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28235415/a-systematic-review-of-health-economic-models-of-opioid-agonist-therapies-in-maintenance-treatment-of-non-prescription-opioid-dependence
#5
Mersha Chetty, James J Kenworthy, Sue Langham, Andrew Walker, William C N Dunlop
BACKGROUND: Opioid dependence is a chronic condition with substantial health, economic and social costs. The study objective was to conduct a systematic review of published health-economic models of opioid agonist therapy for non-prescription opioid dependence, to review the different modelling approaches identified, and to inform future modelling studies. METHODS: Literature searches were conducted in March 2015 in eight electronic databases, supplemented by hand-searching reference lists and searches on six National Health Technology Assessment Agency websites...
February 24, 2017: Addiction Science & Clinical Practice
https://www.readbyqxmd.com/read/28212972/variation-in-health-technology-assessment-and-reimbursement-processes-in-europe
#6
Ronald L Akehurst, Eric Abadie, Noël Renaudin, François Sarkozy
BACKGROUND: It has been suggested that differences in health technology assessment (HTA) processes among countries, particularly within Europe, have led to inequity in patient access to new medicines. OBJECTIVES: To provide an up-to-date snapshot analysis of the present status of HTA and reimbursement systems in select European countries, and to investigate the implications of these processes, especially with regard to delays in market and patient access. METHODS: HTA and reimbursement processes were assessed through a review of published and gray literature, and through a series of interviews with HTA experts...
January 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28207548/egfr-mutation-testing-in-blood-for-guiding-egfr-tyrosine-kinase-inhibitor-treatment-in-patients-with-nonsmall-cell-lung-cancer-a-protocol-for-systematic-review-and-meta-analysis
#7
Jin-Qiu Yuan, Yue-Lun Zhang, Hai-Tao Li, Chen Mao
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing in tumor tissue is now a common practice in selecting non-small cell lung cancer (NSCLC) patients for EGFR tyrosine kinase inhibitor (TKI) treatment. However, tumor tissues are often absent or insufficient for the testing. Blood is a potential substitute providing a noninvasive, easily accessible and repeatedly measureable source of genotypic information. However which is the best blood EGFR mutation testing method remains unclear...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28205056/analyzing-health-related-quality-of-life-data-to-estimate-parameters-for-cost-effectiveness-models-an-example-using-longitudinal-eq-5d-data-from-the-shift-randomized-controlled-trial
#8
Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher
INTRODUCTION: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure. METHODS: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28203120/international-lessons-in-new-methods-for-grading-and-integrating-cost-effectiveness-evidence-into-clinical-practice-guidelines
#9
REVIEW
Kathryn M Antioch, Michael F Drummond, Louis W Niessen, Hindrik Vondeling
Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can enable economists to include economic information on health care provision. Application of economic evidence in CPGs, and its integration into clinical practice and national decision making is hampered by objections from professions, paucity of economic evidence or lack of policy commitment. The use of state-of-art economic methodologies will improve this. Economic evidence can be graded by 'checklists' to establish the best evidence for decision making given methodological rigor...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28202031/making-sense-of-complexity-in-context-and-implementation-the-context-and-implementation-of-complex-interventions-cici-framework
#10
Lisa M Pfadenhauer, Ansgar Gerhardus, Kati Mozygemba, Kristin Bakke Lysdahl, Andrew Booth, Bjørn Hofmann, Philip Wahlster, Stephanie Polus, Jacob Burns, Louise Brereton, Eva Rehfuess
BACKGROUND: The effectiveness of complex interventions, as well as their success in reaching relevant populations, is critically influenced by their implementation in a given context. Current conceptual frameworks often fail to address context and implementation in an integrated way and, where addressed, they tend to focus on organisational context and are mostly concerned with specific health fields. Our objective was to develop a framework to facilitate the structured and comprehensive conceptualisation and assessment of context and implementation of complex interventions...
February 15, 2017: Implementation Science: IS
https://www.readbyqxmd.com/read/28195244/health-technology-assessment-introducing-a-vacuum-based-preservation-system-for-biological-materials-in-the-anatomic-pathology-workflow
#11
R Saliceti, E Nicodemo, A Giannini, A Cortese
INTRODUCTION: The objective of this work is to assess the implementation of a newly introduced medical equipment technology for the vacuum-based preservation of biological materials within an Anatomic Pathology service. METHODS: The approach selected for the analysis is the Health Technology Assessment (HTA ), a comprehensive evaluation method based on relevant scientific evidence and designed to support healthcare decision makers in purchasing, replacing or disposing of technologies...
March 2016: Pathologica
https://www.readbyqxmd.com/read/28194657/eq-5d-and-the-euroqol-group-past-present-and-future
#12
REVIEW
Nancy J Devlin, Richard Brooks
Over the period 1987-1991 an inter-disciplinary five-country group developed the EuroQol instrument, a five-dimensional three-level generic measure subsequently termed the 'EQ-5D'. It was designed to measure and value health status. The salient features of its development and its consolidation and expansion are discussed. Initial expansion came, in particular, in the form of new language versions. Their development raised translation and semantic issues, experience with which helped feed into the design of two further instruments, the EQ-5D-5L and the youth version EQ-5D-Y...
February 13, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28194254/long-term-continuous-ambulatory-ecg-monitors-and-external-cardiac-loop-recorders-for-cardiac-arrhythmia-a-health-technology-assessment
#13
(no author information available yet)
BACKGROUND: Ambulatory electrocardiography (ECG) monitors are often used to detect cardiac arrhythmia. For patients with symptoms, an external cardiac loop recorder will often be recommended. The improved recording capacity of newer Holter monitors and similar devices, collectively known as longterm continuous ambulatory ECG monitors, suggests that they will perform just as well as, or better than, external loop recorders. This health technology assessment aimed to evaluate the effectiveness, cost-effectiveness, and budget impact of longterm continuous ECG monitors compared with external loop recorders in detecting symptoms of cardiac arrhythmia...
2017: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/28186060/model-driven-paediatric-cardiomyopathy-pathways-a-clinical-impact-assessment
#14
Karl A Stroetmann, Rainer Thiel
Intermediate results from an ongoing health technology assessment exercise of a simulation model of paediatric cardiomyopathy are reported. Comprehensive data on paediatric cardiomyopathy/heart failure, treatment options, incidence and prevalence, prognoses for different outcomes to be expected were collected. Based on this knowledge, a detailed clinical pathway model was developed and validated against the clinical workflow in a tertiary paediatric care hospital. It combines three disease stages and various treatment options with estimates of the probabilities of a child moving from one stage to another...
2017: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/28152737/financial-risk-sharing-agreements-using-options-to-make-marginal-benefits-cost-effective
#15
(no author information available yet)
: 41 Background: New cancer treatments have become increasingly costly. Although new drugs may be sufficiently cost-efficiency for a primary indication (i1) to receive funding, subsequent indications (ia) may not prove cost-effective. A financial risk-sharing agreement to increase access is proposed. A potential 2012 real-world implementation in Canada for pazopanib use in metastatic renal cell carcinoma (mRCC) as i1, and soft-tissue sarcoma (STS) as ia is presented. METHODS: The market value of an indication can be approximated by its net-present-value (NPV) of expected cash flows...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28148947/regulatory-watch-outcomes-of-early-health-technology-assessment-dialogues-in-medicinal-product-development
#16
François Maignen, Leeza Osipenko, Pilar Pinilla-Dominguez, Emily Crowe
No abstract text is available yet for this article.
February 2, 2017: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/28145220/the-clinical-effectiveness-of-individual-behaviour-change-interventions-to-reduce-risky-sexual-behaviour-after-a-negative-human-immunodeficiency-virus-test-in-men-who-have-sex-with-men-systematic-and-realist-reviews-and-intervention-development
#17
Paul Flowers, Olivia Wu, Karen Lorimer, Bipasha Ahmed, Hannah Hesselgreaves, Jennifer MacDonald, Sandi Cayless, Sharon Hutchinson, Lawrie Elliott, Ann Sullivan, Dan Clutterbuck, Michael Rayment, Lisa McDaid
BACKGROUND: Men who have sex with men (MSM) experience significant inequalities in health and well-being. They are the group in the UK at the highest risk of acquiring a human immunodeficiency virus (HIV) infection. Guidance relating to both HIV infection prevention, in general, and individual-level behaviour change interventions, in particular, is very limited. OBJECTIVES: To conduct an evidence synthesis of the clinical effectiveness of behaviour change interventions to reduce risky sexual behaviour among MSM after a negative HIV infection test...
January 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28139093/adoption-decisions-for-medical-devices-in-the-field-of-cardiology-results-from-a-european-survey
#18
Maximilian H M Hatz, Jonas Schreyögg, Aleksandra Torbica, Giuseppe Boriani, Carl R B Blankart
Decisions to adopt medical devices at the hospital level have consequences for health technology assessment (HTA) on system level and are therefore important to decision makers. Our aim was to investigate the characteristics of organizations and individuals that are more inclined to adopt and utilize cardiovascular devices based on a comprehensive analysis of environmental, organizational, individual, and technological factors and to identify corresponding implications for HTA. Seven random intercept hurdle models were estimated using the data obtained from 1249 surveys completed by members of the European Society of Cardiology...
February 2017: Health Economics
https://www.readbyqxmd.com/read/28139092/the-role-of-learning-in-health-technology-assessments-an-empirical-assessment-of-endovascular-aneurysm-repairs-in-german-hospitals
#19
Yauheniya Varabyova, Carl Rudolf Blankart, Jonas Schreyögg
Changes in performance due to learning may dynamically influence the results of a technology evaluation through the change in effectiveness and costs. In this study, we estimate the effect of learning using the example of two minimally invasive treatments of abdominal aortic aneurysms: endovascular aneurysm repair (EVAR) and fenestrated EVAR (fEVAR). The analysis is based on the administrative data of over 40,000 patients admitted with unruptured abdominal aortic aneurysm to more than 500 different hospitals over the years 2006 to 2013...
February 2017: Health Economics
https://www.readbyqxmd.com/read/28139087/linking-the-regulatory-and-reimbursement-processes-for-medical-devices-the-need-for-integrated-assessments
#20
Oriana Ciani, Britni Wilcher, Anoukh van Giessen, Rod S Taylor
Much criticism has been directed at the licencing requirements for medical devices (MDs) as they often result in a lack of robust evidence to inform health technology assessment (HTA) decisions. To better understand the current international decisional framework on MD technologies, we undertook three linked research studies: a review of the device regulatory procedures, a survey of current HTA practices and an empirical comparison of HTA reports of drugs versus MDs. Our review confirms that current device regulatory processes across the globe are substantially less stringent than drugs...
February 2017: Health Economics
keyword
keyword
9540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"